Consensus Immix Biopharma, Inc.

Equities

IMMX

US45258H1068

Real-time Estimate Cboe BZX Other stock markets 03:29:34 2024-05-09 pm EDT			5-day change	1st Jan Change
2.145 ^USD	-4.24%		-7.58%	-69.15%

May. 06	Certain Warrants of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI
May. 06	Certain Options of Immix Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI

Evolution of the average Target Price on Immix Biopharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d9983379baff54b594281f3.FlnHilubMng9E64cHB1BZCudukRV9_-jj8xQWcY5BBQ.RT7_223eYi9lWMdWL1NwCmzH7DIfuazP7qkoPPJeQmdbNf_fHspCGwxJlg~b55e67752b655bf8b647ee3d18f5f6e7

Analyst Recommendations on Immix Biopharma, Inc.

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma	23-10-02	CI
Immix Biopharma Unit Says NXC-201 Shows 100% Overall Response Rate in Light Chain Amyloidosis Study	23-05-22	MT
Roth MKM Initiates Immix Biopharma to Buy Rating With $14 Price Target	23-02-22	MT
Immix Unit Says AL Amyloidosis Drug Candidate Showed 100% Complete Response Rate in Clinical Study	23-01-06	MT
Immix Biopharma Says Cancer Drug IMX-110 Showed Higher Survival Rate Versus Johnson & Johnson Unit's Trabectedin in Mice Study	22-05-20	MT
Immix Biopharma Says IMX-110 Candidate Elicits 50% Response Rate in Soft Tissue Sarcoma Study in Mice	22-01-12	MT
Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study	22-01-12	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.24 USD

Average target price

14 USD

Spread / Average Target

+525.00%

High Price Target

14 USD

Spread / Highest target

+525.00%

Low Price Target

14 USD

Spread / Lowest Target

+525.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immix Biopharma, Inc.

Roth MKM

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar